OncoStatyx LLC, a preclinical stage biotechnology company in Cleveland, said it has formed a joint venture with a San Francisco company that is aimed at treating solid tumor cancers.
The joint venture with Atomwise Inc., which uses artificial intelligence to help discover new medicine, will “develop small-molecule compounds that inhibit KDM5B, lysine-specific demethylase 5B, a key epigenetic modulator protein, as an anti-cancer agent, especially for triple-negative breast cancer,” or TNBC, the companies said in a news release.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published September 10, 2019.